secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001701478-25-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q2 net loss $2.9M; cash $1.0M; ATR-12 Phase 1b shows safety
------------------------------------------------------------------

- Net loss of $2.9M for Q2 2025, up from $2.6M in Q2 2024; R&D spend $1.4M, G&A $1.5M.
- Cash and equivalents $1.0M as of June 30, 2025; entered $20M equity line with Alumni Capital LP.
- ATR-12 Phase 1b in Netherton syndrome: 50% enrolled, promising safety in first 5 patients.
- ATR-04 Phase 1/2 for EGFRi rash: design presented at ASCO; first patient dosing expected Q3 2025.
- Anticipated topline data for ATR-12 in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/0001701478-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/aztr-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001701478-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer